Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
BACKGROUND: This was a prospective phase II study of cisplatin and bortezomib (CB) in the first line treatment of malignant pleural mesothelioma (MPM) with validation of progression free survival rate at 18 weeks (PFSR-18)(1) as primary end-point. METHODS: Chemotherapy-naïve patients with histologi...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797090378132750336 |
|---|---|
| author | O'Brien, M Gaafar, R Popat, S Grossi, F Price, A Talbot, D Cufer, T Ottensmeier, C Danson, S Pallis, A Hasan, B Van Meerbeeck, J Baas, P |
| author_facet | O'Brien, M Gaafar, R Popat, S Grossi, F Price, A Talbot, D Cufer, T Ottensmeier, C Danson, S Pallis, A Hasan, B Van Meerbeeck, J Baas, P |
| author_sort | O'Brien, M |
| collection | OXFORD |
| description | BACKGROUND: This was a prospective phase II study of cisplatin and bortezomib (CB) in the first line treatment of malignant pleural mesothelioma (MPM) with validation of progression free survival rate at 18 weeks (PFSR-18)(1) as primary end-point. METHODS: Chemotherapy-naïve patients with histologically proven MPM and performance status (PS) 0/1, were treated with cisplatin 75 mg/m(2) on day 1 and bortezomib 1.3mg/m(2) on days 1, 4, 8, 11 every 3 weeks. The primary end-point validation utilised the landmark method. RESULTS: Between 2007 and 2010 82 patients were entered. PFSR-18 was 53% (80% confidence intervals, CIs, 42-64%). The overall survival (OS) was 13.5 months (95% CI 10.5-15) with 56% (95% CI 44-66%) alive at 1 year. The median PFS was 5.1months (95% CI 3.3-6.5) and the response rate was 28.4% (95% CI 18.9-39.5%). The most frequent grade 3-4 toxicities were hyponatremia (46%), hypokalaemia (17%), fatigue (12.2%), thrombocytopenia (11%), neutropenia (9.7%) and neurotoxicity (motor, sensory, other: 1.2%, 8.5%, 2.4%). There were two toxic deaths (32 and 74days) due to acute pneumonitis and cardiac arrest. End-point validation showed that patients with no progression/progression at 18 weeks had median OS of 16.9/11.9 months, respectively. Hazard ratio was 0.46 (CI 0.32-0.67), logrank test and C-index were 0.007 and 0.60. CONCLUSION: The 50% PFSR-18 for CB was contained within the 80% CI for (42-64%). Therefore the null hypothesis could not be rejected. Accordingly this combination does not warrant further investigation. PFSR-18 was confirmed as a strong predictor of survival. |
| first_indexed | 2024-03-07T03:17:43Z |
| format | Journal article |
| id | oxford-uuid:b65ca4de-330c-4da4-9a65-4ae4fd7b1972 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:17:43Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:b65ca4de-330c-4da4-9a65-4ae4fd7b19722022-03-27T04:40:29ZPhase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b65ca4de-330c-4da4-9a65-4ae4fd7b1972EnglishSymplectic Elements at Oxford2013O'Brien, MGaafar, RPopat, SGrossi, FPrice, ATalbot, DCufer, TOttensmeier, CDanson, SPallis, AHasan, BVan Meerbeeck, JBaas, P BACKGROUND: This was a prospective phase II study of cisplatin and bortezomib (CB) in the first line treatment of malignant pleural mesothelioma (MPM) with validation of progression free survival rate at 18 weeks (PFSR-18)(1) as primary end-point. METHODS: Chemotherapy-naïve patients with histologically proven MPM and performance status (PS) 0/1, were treated with cisplatin 75 mg/m(2) on day 1 and bortezomib 1.3mg/m(2) on days 1, 4, 8, 11 every 3 weeks. The primary end-point validation utilised the landmark method. RESULTS: Between 2007 and 2010 82 patients were entered. PFSR-18 was 53% (80% confidence intervals, CIs, 42-64%). The overall survival (OS) was 13.5 months (95% CI 10.5-15) with 56% (95% CI 44-66%) alive at 1 year. The median PFS was 5.1months (95% CI 3.3-6.5) and the response rate was 28.4% (95% CI 18.9-39.5%). The most frequent grade 3-4 toxicities were hyponatremia (46%), hypokalaemia (17%), fatigue (12.2%), thrombocytopenia (11%), neutropenia (9.7%) and neurotoxicity (motor, sensory, other: 1.2%, 8.5%, 2.4%). There were two toxic deaths (32 and 74days) due to acute pneumonitis and cardiac arrest. End-point validation showed that patients with no progression/progression at 18 weeks had median OS of 16.9/11.9 months, respectively. Hazard ratio was 0.46 (CI 0.32-0.67), logrank test and C-index were 0.007 and 0.60. CONCLUSION: The 50% PFSR-18 for CB was contained within the 80% CI for (42-64%). Therefore the null hypothesis could not be rejected. Accordingly this combination does not warrant further investigation. PFSR-18 was confirmed as a strong predictor of survival. |
| spellingShingle | O'Brien, M Gaafar, R Popat, S Grossi, F Price, A Talbot, D Cufer, T Ottensmeier, C Danson, S Pallis, A Hasan, B Van Meerbeeck, J Baas, P Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). |
| title | Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). |
| title_full | Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). |
| title_fullStr | Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). |
| title_full_unstemmed | Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). |
| title_short | Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). |
| title_sort | phase ii study of first line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end point for mesothelioma clinical trials european organisation for research and treatment of cancer 08052 |
| work_keys_str_mv | AT obrienm phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT gaafarr phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT popats phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT grossif phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT pricea phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT talbotd phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT cufert phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT ottensmeierc phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT dansons phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT pallisa phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT hasanb phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT vanmeerbeeckj phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 AT baasp phaseiistudyoffirstlinebortezomibandcisplatininmalignantpleuralmesotheliomaandprospectivevalidationofprogressionfreesurvivalrateasaprimaryendpointformesotheliomaclinicaltrialseuropeanorganisationforresearchandtreatmentofcancer08052 |